Summary
Updated Aug 31, 2026
Svetlana Ni Makhni is Chief Financial Officer of Prime Medicine, Inc. (PRME). 1 SEC Form 4 filing on record, dated 18 April 2026.
Trading Pattern
InsiderAlpha's records for Svetlana Ni Makhni go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who have reported open-market trades at the same companies as Svetlana Ni Makhni. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners X, LLC - $10.00M of PRME open-market activity on record
- Robert Nelsen - $10.00M of PRME open-market activity on record
- ARCH Venture Partners XII, LLC - $10.00M of PRME open-market activity on record
- GV 2021 GP, L.L.C. - $4.95M of PRME open-market activity on record
- David R. Liu - $53K of PRME open-market activity on record
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Svetlana Ni Makhni?
Svetlana Ni Makhni is a corporate insider, tracked as Chief Financial Officer of Prime Medicine, Inc. (PRME). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Svetlana Ni Makhni last file a Form 4?
The only primary Form 4 on record is dated 18 April 2026.
Where can I see all of Svetlana Ni Makhni's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Svetlana Ni Makhni and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial